Comprehensively profiling of molecular landscape using mHSPC patient (scRNA-Seq).

Although many treatment options have been adopted in patients with metastatic hormone sensitive prostate cancer (mHSPC), such as early docetaxel and AR-targeting therapy, there are currently no optimal biomarkers to guide treatment in these patients. To understand the transcriptomic features in mHSPC patients treated by either docetaxel or abiraterone acetate by performing whole transcriptome sequencing (WTS) and single cell RNA sequencing (scRNA-seq). Overall design: Single-cell and bulk RNA-seq provide a comprehensive transcriptomic gene expression atlas for mHSPC.